MA48462A - Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation - Google Patents

Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation

Info

Publication number
MA48462A
MA48462A MA048462A MA48462A MA48462A MA 48462 A MA48462 A MA 48462A MA 048462 A MA048462 A MA 048462A MA 48462 A MA48462 A MA 48462A MA 48462 A MA48462 A MA 48462A
Authority
MA
Morocco
Prior art keywords
methods
rankl antibodies
human
human anti
rankl
Prior art date
Application number
MA048462A
Other languages
English (en)
Other versions
MA48462B1 (fr
Inventor
Stephen Robert Brych
Jaymille Fallon
Pavan K Ghattyvenkatakrishna
Monica Michelle Goss
Jian Hua Gu
Lyanne M Wong
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62165668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA48462(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA48462A publication Critical patent/MA48462A/fr
Publication of MA48462B1 publication Critical patent/MA48462B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA48462A 2017-04-28 2018-04-27 Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation MA48462B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492056P 2017-04-28 2017-04-28
PCT/US2018/029728 WO2018200918A1 (fr) 2017-04-28 2018-04-27 Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation

Publications (2)

Publication Number Publication Date
MA48462A true MA48462A (fr) 2020-03-04
MA48462B1 MA48462B1 (fr) 2024-05-31

Family

ID=62165668

Family Applications (2)

Application Number Title Priority Date Filing Date
MA48462A MA48462B1 (fr) 2017-04-28 2018-04-27 Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation
MA62173A MA62173B1 (fr) 2017-04-28 2018-04-27 Formulations d'anticorps anti-rankl humains et leurs procédés d'utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA62173A MA62173B1 (fr) 2017-04-28 2018-04-27 Formulations d'anticorps anti-rankl humains et leurs procédés d'utilisation

Country Status (37)

Country Link
US (3) US11192952B2 (fr)
EP (3) EP4477667A3 (fr)
JP (4) JP7190822B2 (fr)
KR (2) KR20240110083A (fr)
CN (2) CN118987200A (fr)
AR (1) AR111497A1 (fr)
AU (2) AU2018260750B2 (fr)
BR (1) BR112019022188A2 (fr)
CA (1) CA3054165A1 (fr)
CL (3) CL2019003032A1 (fr)
CO (1) CO2019011463A2 (fr)
CR (2) CR20250034A (fr)
DK (2) DK4190355T3 (fr)
EA (1) EA201992570A1 (fr)
ES (2) ES2973572T3 (fr)
FI (2) FI3615066T3 (fr)
HR (2) HRP20241604T1 (fr)
HU (2) HUE065544T2 (fr)
IL (2) IL293127B2 (fr)
JO (2) JOP20190255A1 (fr)
LT (2) LT4190355T (fr)
MA (2) MA48462B1 (fr)
MX (1) MX2023013460A (fr)
MY (1) MY202479A (fr)
PE (2) PE20200343A1 (fr)
PH (1) PH12019502444A1 (fr)
PL (2) PL4190355T3 (fr)
PT (2) PT4190355T (fr)
RS (2) RS65299B1 (fr)
SG (1) SG11201909998TA (fr)
SI (2) SI3615066T1 (fr)
SM (2) SMT202400491T1 (fr)
TN (2) TN2021000055A1 (fr)
TW (2) TWI903512B (fr)
UY (2) UY37707A (fr)
WO (1) WO2018200918A1 (fr)
ZA (1) ZA202205141B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018200533A1 (fr) * 2017-04-28 2018-11-01 Amgen Inc. Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
JOP20190255A1 (ar) 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
KR20210079373A (ko) * 2018-11-16 2021-06-29 삼성바이오에피스 주식회사 단백질을 포함하는 안정한 액상 조성물
CN109374779A (zh) * 2018-12-17 2019-02-22 杭州奕安济世生物药业有限公司 一种蔗糖含量的快速检测方法
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
US20220332846A1 (en) * 2019-09-19 2022-10-20 Innovent Biologics (Suzhou) Co., Ltd. Use of anti-pcsk9 antibody in method for preventing or treating cholesterol-related disease
CN111704670B (zh) * 2020-08-18 2020-11-03 迈威(上海)生物科技股份有限公司 重组抗RANKL抗体IgG2型的二硫键异构体及其纯化方法
CA3197104A1 (fr) * 2020-11-11 2022-05-19 Hq Han Antagonistes bifonctionnels de l'activine/tgf-beta et rankl et leurs utilisations
CA3218542A1 (fr) * 2021-05-12 2022-11-17 Hua Ying Molecule de liaison a l'antigene se liant specifiquement a rankl et ngf, et son utilisation medicale
WO2023018870A1 (fr) 2021-08-12 2023-02-16 Amgen Inc. Formulations d'anticorps
US20250297020A1 (en) * 2021-11-23 2025-09-25 Adalta Limited Rank-l binding molecules
WO2023179791A1 (fr) * 2022-03-24 2023-09-28 Angitia Biomedicines Limited Traitement de troubles musculo-squelettiques
EP4590707A1 (fr) 2022-09-23 2025-07-30 The University of North Carolina at Chapel Hill Méthodes et compositions pharmaceutiques destinées au traitement du mélanome
EP4620483A4 (fr) * 2022-11-16 2026-03-18 Suzhou Suncadia Biopharmaceuticals Co Ltd Composition pharmaceutique comprenant des anticorps bispécifiques anti-rankl-ngf
AU2024232412A1 (en) * 2023-03-03 2025-09-25 Alvotech Hf Denosumab formulation
WO2025036493A1 (fr) * 2023-08-17 2025-02-20 Sinomab Bioscience Limited Anticorps ciblant les protéines rankl et sclérostine et leurs utilisations
WO2025116648A1 (fr) * 2023-12-01 2025-06-05 삼성바이오에피스 주식회사 FORMULATION LIQUIDE STABLE SANS TAMPON D'ANTICORPS ANTI-IL-4Rα

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
CA2672902C (fr) * 2006-12-21 2012-11-27 Amgen Inc. Formulations
WO2009002521A2 (fr) 2007-06-25 2008-12-31 Amgen Inc. Compositions d'agents de liaison spécifiques vis-à-vis du facteur de croissance des hépatocytes
SG10201402265YA (en) * 2008-02-07 2014-08-28 Amgen Inc Stabilized protein compositions
AR073072A1 (es) 2008-08-19 2010-10-13 Regeneron Pharma Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
CA2734275A1 (fr) 2008-09-10 2010-03-18 Genentech, Inc. Compositions et procedes permettant d'eviter la degradation oxydative des proteines
US9265834B2 (en) * 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
TWI440470B (zh) 2009-03-19 2014-06-11 Chugai Pharmaceutical Co Ltd 含改良抗體分子之醫藥配方
EP2568960B1 (fr) 2010-05-10 2018-06-06 Intas Pharmaceuticals Ltd. PRÉPARATION LIQUIDE DE POLYPEPTIDES CONTENANT UN DOMAINE Fc D'UNE IMMUNOGLOBULINE
EP2433644A1 (fr) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Traitement du cancer du sein
BR112013025845A2 (pt) 2011-04-07 2018-09-04 Glaxosmithkline Llc formulações com viscosidade reduzida
WO2013012022A1 (fr) 2011-07-19 2013-01-24 中外製薬株式会社 Préparation à teneur en protéines stable renfermant de l'argininamide ou un composé analogue correspondant
CN104023748B (zh) 2011-10-28 2018-03-02 诚信生物公司 含有氨基酸的蛋白质制剂
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
TW201542226A (zh) 2014-02-12 2015-11-16 Sanofi Sa 抗－ｉｌ－４／抗－ｉｌ－１３雙特異性抗體／聚麩胺酸配製物
WO2015134406A1 (fr) * 2014-03-03 2015-09-11 La Jolla Biologics, Inc. Préparations aqueuses stables de protéine recombinée
AU2015257798C1 (en) 2014-05-07 2020-10-22 Takeda Pharmaceutical Company Limited Liquid formulation comprising GM-CSF neutralizing compound
US20180000932A1 (en) 2014-12-31 2018-01-04 Novelmed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies
WO2016162819A1 (fr) 2015-04-07 2016-10-13 Lupin Limited Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha
JOP20190255A1 (ar) 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها

Also Published As

Publication number Publication date
UY37707A (es) 2018-10-31
JP7190822B2 (ja) 2022-12-16
LT4190355T (lt) 2024-12-27
AR111497A1 (es) 2019-07-17
JOP20240115B1 (ar) 2025-10-01
IL268704B (en) 2022-06-01
IL268704A (en) 2019-10-31
SMT202400095T1 (it) 2024-05-14
CA3054165A1 (fr) 2018-11-01
CR20250034A (es) 2025-03-06
BR112019022188A2 (pt) 2020-05-12
EP4477667A3 (fr) 2025-05-07
TWI903512B (zh) 2025-11-01
TN2021000055A1 (en) 2022-10-03
PE20251534A1 (es) 2025-06-05
US11192952B2 (en) 2021-12-07
AU2025205470A1 (en) 2025-08-14
RS65299B1 (sr) 2024-04-30
MX2023013460A (es) 2023-12-15
KR102681171B1 (ko) 2024-07-05
EA201992570A1 (ru) 2020-03-20
HRP20241604T1 (hr) 2025-01-31
CL2019003032A1 (es) 2020-02-21
US20220143181A1 (en) 2022-05-12
CL2023002505A1 (es) 2024-03-08
PH12019502444A1 (en) 2020-07-20
AU2018260750B2 (en) 2025-04-17
TW201841654A (zh) 2018-12-01
CN110621342B (zh) 2024-08-02
SG11201909998TA (en) 2019-11-28
ES2997833T3 (en) 2025-02-18
KR20190140464A (ko) 2019-12-19
TWI839331B (zh) 2024-04-21
PL4190355T3 (pl) 2025-02-10
JP7356525B2 (ja) 2023-10-04
IL293127B2 (en) 2024-06-01
UY40974A (es) 2024-12-13
US20200354463A1 (en) 2020-11-12
DK3615066T5 (da) 2024-09-02
MA62173B1 (fr) 2025-01-31
IL293127B1 (en) 2024-02-01
EP3615066A1 (fr) 2020-03-04
TW202435914A (zh) 2024-09-16
LT3615066T (lt) 2024-02-26
CN110621342A (zh) 2019-12-27
EP4190355A1 (fr) 2023-06-07
RS66284B1 (sr) 2025-01-31
SI3615066T1 (sl) 2024-04-30
JP2025093923A (ja) 2025-06-24
EP4477667A2 (fr) 2024-12-18
CL2020002012A1 (es) 2020-10-16
HUE069382T2 (hu) 2025-03-28
US20250326853A1 (en) 2025-10-23
AU2018260750A1 (en) 2019-08-29
FI4190355T3 (fi) 2024-12-07
EP4190355B1 (fr) 2024-09-25
PT3615066T (pt) 2024-03-08
MA48462B1 (fr) 2024-05-31
PE20200343A1 (es) 2020-02-14
PL3615066T3 (pl) 2024-04-29
FI3615066T3 (fi) 2024-02-29
JP2022062059A (ja) 2022-04-19
ZA202205141B (en) 2025-04-30
ES2973572T3 (es) 2024-06-20
HRP20240167T1 (hr) 2024-04-26
DK3615066T3 (da) 2024-03-11
MY202479A (en) 2024-04-30
IL293127A (en) 2022-07-01
SI4190355T1 (sl) 2025-02-28
WO2018200918A1 (fr) 2018-11-01
HUE065544T2 (hu) 2024-05-28
CR20190538A (es) 2020-02-26
JOP20190255A1 (ar) 2019-10-27
JP2018188430A (ja) 2018-11-29
WO2018200918A8 (fr) 2019-10-17
EP3615066B1 (fr) 2023-12-27
CN118987200A (zh) 2024-11-22
SMT202400491T1 (it) 2025-01-14
US11873343B2 (en) 2024-01-16
DK4190355T3 (da) 2024-12-09
TN2019000297A1 (en) 2021-05-07
JP2023166396A (ja) 2023-11-21
PT4190355T (pt) 2024-12-05
KR20240110083A (ko) 2024-07-12
CO2019011463A2 (es) 2019-10-31

Similar Documents

Publication Publication Date Title
MA48462A (fr) Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation
FR24C1050I1 (fr) Récepteurs d'antigènes chimériques basés sur des anticorps à domaine unique et leurs méthodes d'utilisation
EP3852805A4 (fr) Anticorps anti-lilrb2 et leurs méthodes d'utilisation
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
FR24C1044I2 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
EP3383430A4 (fr) Anticorps et leurs méthodes d'utilisation
EP3917564A4 (fr) Anticorps anti-claudine 18 et leurs méthodes d'utilisation
EP3525583A4 (fr) Anticorps anti-c1s et leurs méthodes d'utilisation
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA71409A (fr) Constructions d'anticorps pour dll3 et cd3
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
MA50354A (fr) Anticorps ciblant le cd137 et leurs méthodes d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
EP3472200A4 (fr) Anticorps anti-myostatine et leurs procédés d'utilisation
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
EP3472316A4 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
MA42971A (fr) Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
EP3728323A4 (fr) Anticorps anti-fzd et méthodes d'utilisation
EP3684819A4 (fr) Anticorps anti-ykl40 et méthodes d'utilisation
EP3436476A4 (fr) Anticorps anti-ryk et leurs procédés d'utilisation
EP3491025A4 (fr) Anticorps fcrn et leurs procédés d'utilisation